Arcutis Biotherapeutics (ARQT) Shares Outstanding (2019 - 2026)
Arcutis Biotherapeutics (ARQT) posted quarterly Shares Outstanding (Entity) of $129365.0 for Q1 2026, down 99.89% year-over-year from $119.1 million in Q1 2025, and down 99.9% quarter-over-quarter from $123.3 million in Q4 2025.
Arcutis Biotherapeutics (ARQT) Shares Outstanding (2019 - 2026) Analysis & Trends
Arcutis Biotherapeutics' Shares Outstanding (Entity) history runs 8 years deep, the most recent figure standing at $129365.0 for Q1 2026.
- In Q1 2026, Shares Outstanding (Entity) fell 99.89% year-over-year to $129365.0; the TTM figure through Mar 2026 stood at $129365.0 (down 99.89% YoY), while the FY2025 annual figure was $123.3 million, up 4.65% from the prior year.
- Shares Outstanding (Entity) for Q1 2026 stood at $129365.0, down from $123.3 million in the prior quarter.
- The five-year high for Shares Outstanding (Entity) was $123.3 million in Q4 2025, with the low at $129365.0 in Q1 2026.
- The 5-year median for Shares Outstanding (Entity) is $69.3 million (2023), against an average of $84.0 million.
- The sharpest annual moves came in 2024 and 2026: Shares Outstanding (Entity) soared 89.14% in 2024, then slumped 99.89% in 2026.
- Arcutis Biotherapeutics' Shares Outstanding (Entity) stood at $61.0 million in 2022, then rose by 13.55% to $69.3 million in 2023, then soared by 70.04% to $117.8 million in 2024, then rose by 4.65% to $123.3 million in 2025, then slumped by 99.9% to $129365.0 in 2026.
- Business Quant data shows ARQT's Shares Outstanding (Entity) at $129365.0 in Q1 2026, $123.3 million in Q4 2025, and $120.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 62.19 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 210.89 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.45 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 25.05 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 445.06 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 133.61 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 217.35 Mn |
| 10 | Arcutis Biotherapeutics | 3.29 Bn | 3.05 Bn | 118.92 Mn | 130.52 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 130.52 Mn |
| Mar 31, 2026 | 129,365.00 |
| Dec 31, 2025 | 127.23 Mn |
| Sep 30, 2025 | 127.62 Mn |
| Jun 30, 2025 | 127.00 Mn |
| Mar 31, 2025 | 126.04 Mn |
| Dec 31, 2024 | 120.96 Mn |
| Sep 30, 2024 | 124.30 Mn |
| Jun 30, 2024 | 123.48 Mn |
| Mar 31, 2024 | 111.05 Mn |
| Dec 31, 2023 | 69.31 Mn |
| Sep 30, 2023 | 61.73 Mn |
| Jun 30, 2023 | 61.43 Mn |
| Mar 31, 2023 | 61.17 Mn |
| Dec 31, 2022 | 55.03 Mn |
| Sep 30, 2022 | 57.09 Mn |
| Jun 30, 2022 | 51.42 Mn |
| Mar 31, 2022 | 50.51 Mn |
| Dec 31, 2021 | 49.41 Mn |
| Sep 30, 2021 | 50.10 Mn |